In this task, you are given a summary for US Congressional and California state bill, your task is to generate a Title for this bill. The preferred titles are under forty words and mention the purpose of the bill.

Q: Innovation Employment Act - Amends the Immigration and Nationality Act to increase the annual H-1B nonimmigrant visa (specialty occupation) cap from 65,000 to 130,000 starting in FY2008.

Provides that for FY2010-FY2015 if the cap has been reached in the prior year the current cap would increase to the greater of 180,000 and the limitation applicable for the previous year increased by 20% percent.

Exempts from H-1B caps an alien who has earned a master's or higher degree from a U.S. institution of higher education in science, technology, engineering, or mathematics and with respect to whom the petitioning employer requires such education as a condition for employment.

Establishes a 20,000 annual cap for aliens who earned a master's or higher degree from an institution of higher education outside of the United States in science, technology, engineering, or mathematics and with respect to whom the petitioning employer requires such education as a condition for employment.

Revises H-1B provisions to: (1) require an employer to provide specified job information in the employment advertisement; (2) authorize the Secretary of Labor to initiate an H-1B employer investigation; (3) increase employer penalties; and (4) provide whistleblower protections.

A: To modify certain requirements with respect to H-1B nonimmigrants.
****
Q: Federal Health Care Board Act of 2007 - Establishes the Federal Health Care Board as an independent agency in the executive branch.

Requires the Board to: (1) ensure that Americans have access to health insurance and are provided certain basic facts about health care services prior to receiving care; (2) ensure that providers are delivering safe, evidence-based, high quality care and are transparent about pricing through disclosure of actual costs; (3) demand transparency for disclosure of actual costs and pricing from providers and payers through an information clearinghouse; (4) establish a national standard for a basic health insurance plan (including a basic minimum policy and the regional cost for such policy), a national protocol and standard for secure, universal, and individual electronic medical records, a national standard for public health services (including safety net providers), loan forgiveness and scholarship programs for health care providers who serve in underserved areas, and model dispute resolution procedures for malpractice claims that states may adopt; and (5) monitor progress toward those objectives.

Directs the Board's Board of Governors to establish 12 regions of the United States. Establishes in each region a Regional Board, based in a major city, to provide the Board of Governors with considerations that are relevant to their region's population.

A: A bill to provide for the establishment of the Federal Health Care Board.
****
Q: Helping Effective Antibiotics Last Act of 2015 or the HEAL Act This bill amends the Federal Food, Drug, and Cosmetic Act to allow the Food and Drug Administration (FDA) to approve an antibacterial drug or biological product that is intended to treat a serious or life-threatening condition only for treating a well-defined population of patients. To be approved, the antibacterial product must produce superior outcomes over available therapies in the well-defined patient population. A product approved by this pathway must include in its prescribing information the population of patients expected to benefit from using the product and the method for identifying members of that population. The FDA must require each product to have a risk evaluation and mitigation strategy. The Centers for Disease Control and Prevention must monitor changes to bacterial drug resistance and changes to patient outcomes caused by bacterial drug resistance. Upon approval of antibacterial products, the FDA must identify susceptibility test interpretive criteria (the drug concentrations where a type of bacteria is categorized as susceptible, intermediate, or resistant) and update the criteria as needed based upon evidence of changes in patient outcomes. To be eligible for an exclusivity period extension, a qualified infectious disease product must be demonstrated to produce superior outcomes over available therapies. The FDA must issue guidance on the development of target product profiles for antibacterial drugs.

A:
HEAL Act
****